AA
NBIX icon

AQR Arbitrage’s Neurocrine Biosciences NBIX Stock Holding History

AQR Arbitrage’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-196,837
Closed -$15.3M – 409
2017
Q4 		$15.3M Buy
196,837
+12,152
+7% +$829K 0.18% 109
2017
Q3 		$11.3M Buy
184,685
+31,308
+20% +$1.65M 0.12% 129
2017
Q2 		$7.05M Buy
+153,377
New +$7.44M 0.08% 170

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AQR Arbitrage's NBIX Position: Q1 2018 in Review

AQR Arbitrage sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 196,837 shares — an estimated $15.3M sold.

AQR Arbitrage first reported a position in NBIX in Q2 2017 and held it in 3 quarters. The position peaked at $15.3M in Q4 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • AQR Arbitrage reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • AQR Arbitrage sold 196,837 Neurocrine Biosciences shares in Q1 2018, an estimated $15.3M.
  • AQR Arbitrage first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 3 quarters.
  • AQR Arbitrage's Neurocrine Biosciences position peaked at $15.3M in Q4 2017.
  • 267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on AQR Arbitrage's 13F filing for Q1 2018, filed 15 May 2018.